Half-Year 2022 Financial and Clinical Trials Update

Quarterly sales performance: As guided COVID-19 sales coming down in Q2 16% 14% 12% 10% 13% 8% 6% 7% 6% 6% 4% 4% -5% 4% 4% 2% 3% 3% 0% -2% www 14%* 12% 11% 9% 9% 7% 7% 6% 6% 6% 8% 8% 7% 6% 5% 3% 1% 1% 0% -4% -6% -4% AHR¹ impact -8% -10% COVID-19 impact Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 15 15 15 15 16 16 16 16 17 17 17 17 18 18 18 18 19 19 19 19 20 20 20 20 21 21 21 21 22 22 Growth rates at CER (Constant Exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset; 1 AHR: Avastin, Herceptin, Rituxan/MabThera Roche 8

View entire presentation